Compare Equinor ASA (EQNR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Mesoblast Limited — how do they compare? Equinor ASA trades at $43.61 (market cap $101.62B), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: Equinor ASA is far larger — about 58.1× Mesoblast Limited's market cap, and Equinor ASA pays a 3.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Mesoblast Limited for 14 Days on average.
| EQNR | MESO | |
|---|---|---|
Market Cap | $101.62B | $1.75B |
Volume | 4,991,782 | 239,027 |
Sector | Energy | Health |
52-Week High | $45.75 | $20.96 |
52-Week Low | $22.41 | $13.19 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $110.31B | $1.83B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $41.61, down 3.26% today, with a bearish technical outlook and mixed fundamental performance. The stock shows attractive valuation metrics including P/E of 11.63 and EV/EBITDA of 2.39, but faces declining profit margins from 19.29% in 2022 to 4.76% in 2025. Recent earnings show two beats and one miss, while analyst consensus remains positive with a $87.50 price target representing significant upside potential from current levels.
The investment case balances deep value characteristics against operational headwinds. While valuation appears compelling with strong cash flows and dividend payments, investors face risks from volatile energy markets and margin compression. The 112% upside to consensus target suggests Wall Street sees substantial recovery potential if operational performance improves.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
